Cytokinetics(CYTK) - 2024 Q1 - Quarterly Results

SOUTH SAN FRANCISCO, Calif., May 8, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2024. Net loss for the first quarter was $135.6 million, or$1.33 per share, compared to net loss for the first quarter of 2023 of $131.3 million, or$1.38 per share. Cash, cash equivalents and investments totaled $634.3 million at March 31, 2024. "In the first quarter, we advanced our muscle-biology portfolio anchored by the broad development program of aficamten. In para ...